Search > Results

You searched for: EV220152 (EV-TRACK ID)

Showing 1 - 6 of 6

Experiment number
  • If needed, multiple experiments were identified in a single publication based on differing sample types, separation protocols and/or vesicle types of interest.
Species
  • Species of origin of the EVs.
Separation protocol
  • Gives a short, non-chronological overview of the different steps of the separation protocol.
    • (d)(U)C = (differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
Details EV-TRACK ID Experiment nr. Species Sample type Separation protocol First author Year EV-METRIC
EV220152 3/6 Mus musculus 67NR (d)(U)C
DG
Vardaki I 2016 78%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
78% (97th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Density gradient
Protein markers
EV: CD63/ TSG101/ Rab5/ integrin alpha2/ integrin beta1/ periostin/ N-cadherin/ LOXL3/ LOXL4/ Glypican-1/ Glypican-4/ V-ATPase/ Alix/ beta-catenin/ E-cadherin/ Syndecan-4/ Vimentin/ GADPH/ AIF
non-EV: None
Proteomics
yes
EV density (g/ml)
1.12-1.16
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Mus musculus
Sample Type
Cell culture supernatant
EV-producing cells
67NR
EV-harvesting Medium
EV-depleted medium
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Wash: time (min)
120
Wash: speed (g)
120000
Density gradient
Only used for validation of main results
Yes
Lowest density fraction
0.2 M
Highest density fraction
2 M
Orientation
Top-down
Speed (g)
120000
Duration (min)
1200
Fraction processing
Centrifugation
Pelleting: duration (min)
120
Pelleting: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
CD63/ TSG101/ Rab5/ integrin alpha2/ integrin beta1/ periostin/ N-cadherin/ LOXL3/ LOXL4/ Glypican-1/ Glypican-4/ V-ATPase/ Alix
Not detected EV-associated proteins
beta-catenin/ E-cadherin/ Syndecan-4/ Vimentin/ GADPH/ AIF
Flow cytometry aspecific beads
Flow cytometry specific beads
Detected EV-associated proteins
CD63
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
89
EV concentration
Yes
EM
EM-type
Transmission­-EM
Image type
Close-up, Wide-field
EV220152 4/6 Mus musculus 4T1 (d)(U)C
DG
Vardaki I 2016 78%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
78% (97th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Density gradient
Protein markers
EV: CD63/ TSG101/ Rab5/ Alix/ beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ E-cadherin/ LOXL4/ Glypican-1/ V-ATPase/ Alix/ Vimentin/ GAPDH/ AIF/ N-Cadherin/ LOXL3/ Syndecan-4/ Glypican-4/ LOXL3/ N-Cadherin
non-EV: None
Proteomics
yes
EV density (g/ml)
1.12-1.16
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Mus musculus
Sample Type
Cell culture supernatant
EV-producing cells
4T1
EV-harvesting Medium
EV-depleted medium
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Wash: time (min)
120
Wash: speed (g)
120000
Density gradient
Only used for validation of main results
Yes
Lowest density fraction
0.2 M
Highest density fraction
2 M
Orientation
Top-down
Speed (g)
120000
Duration (min)
1200
Fraction processing
Centrifugation
Pelleting: duration (min)
120
Pelleting: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
CD63/ TSG101/ Rab5/ Alix/ beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ E-cadherin/ LOXL4/ Glypican-1/ V-ATPase/ Alix
Not detected EV-associated proteins
Vimentin/ GAPDH/ AIF/ N-Cadherin/ LOXL3/ Syndecan-4/ Glypican-4/ LOXL3/ N-Cadherin
Flow cytometry aspecific beads
Flow cytometry specific beads
Detected EV-associated proteins
CD81
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
102
EV concentration
Yes
EM
EM-type
Transmission­-EM
Image type
Close-up, Wide-field
EV220152 5/6 Homo sapiens Plasma (d)(U)C Vardaki I 2016 44%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
44% (66th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Plasma
Sample origin
Breast cancer, localised
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Protein markers
EV: E-Cadherin/ N-Cadherin/ Periostin/ CD9
non-EV: None
Proteomics
no
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
E-Cadherin/ N-Cadherin/ Periostin/ CD9
Flow cytometry aspecific beads
Flow cytometry specific beads
Detected EV-associated proteins
CD81
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
95
EV concentration
Yes
Particle yield
as number of particles per milliliter of starting sample: 8.35e+9
EM
EM-type
Transmission­-EM
Image type
Close-up
EV220152 6/6 Homo sapiens Plasma (d)(U)C Vardaki I 2016 44%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
44% (66th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Plasma
Sample origin
Breast cancer, lymph-node metastasis
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Protein markers
EV: E-Cadherin/ N-Cadherin/ Periostin/ CD9
non-EV: None
Proteomics
yes
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Plasma
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
E-Cadherin/ N-Cadherin/ Periostin/ CD9
Flow cytometry aspecific beads
Flow cytometry specific beads
Detected EV-associated proteins
CD81
Proteomics database
No
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
125
EV concentration
Yes
Particle yield
as number of particles per milliliter of starting sample: 1.09e+10
EM
EM-type
Transmission­-EM
Image type
Close-up
EV220152 1/6 Homo sapiens MCF7 (d)(U)C Vardaki I 2016 33%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
33% (74th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Protein markers
EV: beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ E-cadherin/ N-cadherin/ CD81/ TSG101/ ERalpha/ p53/ Glypican-1
non-EV: None
Proteomics
no
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
MCF7
EV-harvesting Medium
EV-depleted medium
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Wash: time (min)
120
Wash: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ E-cadherin/ N-cadherin/ CD81/ TSG101/ ERalpha
Not detected EV-associated proteins
p53/ Glypican-1
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
108
EV concentration
Yes
EV220152 2/6 Homo sapiens MDAMB231 (d)(U)C Vardaki I 2016 33%

Study summary

Full title
All authors
Vardaki I, Ceder S, Rutishauser D, Baltatzis G, Foukakis T, Panaretakis T
Journal
Oncotarget
Abstract
Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related (show more...)Breast cancer (BrCa) is the most frequent cancer type in women and a leading cause of cancer related deaths in the world. Despite the decrease in mortality due to better diagnostics and palliative care, there is a lack of prognostic markers of metastasis. Recently, the exploitation of liquid biopsies and in particular of the extracellular vesicles has shown promise in the identification of such prognostic markers. In this study we compared the proteomic content of exosomes derived from metastatic and non-metastatic human (MCF7 and MDA-MB-231) and mouse (67NR and 4T1) cell lines. We found significant differences not only in the amount of secreted exosomes but most importantly in the protein content of exosomes secreted from metastatic versus non-metastatic ones. We identified periostin as a protein that is enriched in exosomes secreted by metastatic cells and validated its presence in a pilot cohort of breast cancer patient samples with localized disease or lymph node (LN) metastasis. (hide)
EV-METRIC
33% (74th percentile of all experiments on the same sample type)
 Reported
 Not reported
 Not applicable
EV-enriched proteins
Protein analysis: analysis of three or more EV-enriched proteins
non EV-enriched protein
Protein analysis: assessment of a non-EV-enriched protein
qualitative and quantitative analysis
Particle analysis: implementation of both qualitative and quantitative methods. For the quantitative method, the reporting of measured EV concentration is expected.
electron microscopy images
Particle analysis: inclusion of a widefield and close-up electron microscopy image
density gradient
Separation method: density gradient, at least as validation of results attributed to EVs
EV density
Separation method: reporting of obtained EV density
ultracentrifugation specifics
Separation method: reporting of g-forces, duration and rotor type of ultracentrifugation steps
antibody specifics
Protein analysis: antibody clone/reference number and dilution
lysate preparation
Protein analysis: lysis buffer composition
Study data
Sample type
Cell culture supernatant
Sample origin
Control condition
Focus vesicles
exosome
Separation protocol
Separation protocol
  • Gives a short, non-chronological overview of the
    different steps of the separation protocol.
    • dUC = (Differential) (ultra)centrifugation
    • DG = density gradient
    • UF = ultrafiltration
    • SEC = size-exclusion chromatography
    • IAF = immuno-affinity capture
(Differential) (ultra)centrifugation
Protein markers
EV: beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ Glypican-1/ N-cadherin/ CD81/ TSG101/ p53/ ERalpha/ E-cadherin
non-EV: None
Proteomics
no
Show all info
Study aim
Biomarker/Identification of content (omics approaches)
Sample
Species
Homo sapiens
Sample Type
Cell culture supernatant
EV-producing cells
MDAMB231
EV-harvesting Medium
EV-depleted medium
Separation Method
(Differential) (ultra)centrifugation
dUC: centrifugation steps
Between 800 g and 10,000 g
Between 100,000 g and 150,000 g
Pelleting performed
Yes
Pelleting: speed (g)
120000
Wash: time (min)
120
Wash: speed (g)
120000
Characterization: Protein analysis
Protein Concentration Method
Bradford
Western Blot
Detected EV-associated proteins
beta-catenin/ integrin alpha2/ integrin beta1/ periostin/ Glypican-1/ N-cadherin/ CD81/ TSG101
Not detected EV-associated proteins
p53/ ERalpha/ E-cadherin
Characterization: Lipid analysis
No
Characterization: Particle analysis
NTA
Report type
Mean
Reported size (nm)
106
EV concentration
Yes
1 - 6 of 6
  • CM = Commercial method
  • dUC = differential ultracentrifugation
  • DG = density gradient
  • UF = ultrafiltration
  • SEC = size-exclusion chromatography
EV-TRACK ID
EV220152
species
Mus
musculus
Mus
musculus
Homo
sapiens
Homo
sapiens
Homo
sapiens
Homo
sapiens
sample type
Cell
culture
Cell
culture
Plasma
Plasma
Cell
culture
Cell
culture
cell type
67NR
4T1
NA
NA
MCF7
MDAMB231
medium
EV-depleted
medium
EV-depleted
medium
NA
NA
EV-depleted
medium
EV-depleted
medium
condition
Control
condition
Control
condition
Breast cancer
localised
Breast cancer
lymph-node
metastasis
Control
condition
Control
condition
separation protocol
dUC/
Density
gradient
dUC/
Density
gradient
dUC
dUC
dUC
dUC
Exp. nr.
3
4
5
6
1
2
EV-METRIC %
78
78
44
44
33
33